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IL-2 represents thedominant growth factor forT lymphocytes, and consequently
plays a central role in the development of an immune response (reviewed in refer-
ence 1) . Additionally, this cytokine has been implicated in intrathymic T cell devel-
opment (2, 3) . Severe combined immunodeficiency disease (SCID) t is a rare, het-
erogeneous, lethal congenital disorder characterized by severe impairment ofTand
B cell function, normally associated with T lymphopenia (4) . Although rare forms
of this disease have been associated with specific enzyme or receptor deficiencies
(5-7), in most cases the defects in lymphocyte development that underlie the im-
munodeficiency are unknown . In this report we describe an unusual SLID patient
with increased T cell numbers and a defect in IL-2 production . The relevance of
these findings for present models ofT cell development are discussed .
Materials and Methods
CellularAnalysis.
￿
PBMC were isolated by Ficoll-Hypaque gradient centrifugation . T cell
proliferation assays were performed as described (8) . IL-2 production was quantitated by
bioassay using the IL-2-dependent murine cell line CTLL-2 (9) . Immunofluorescence was
performed as previously described (8), using mAbs commercially available through Becton
Dickinson & Co. (Mountain View, CA) or Coulter Immunology (Hialeah, FL) . Calcium
mobilization was assayed using the calcium-sensitive dyeFLUO-3 acetoxy-methylester (Mo-
lecular Bioprobes, Eugene, OR) . PBMC were loaded with the dye as recommended by the
manufacturer. Cellular fluorescence was measured at fixed intervals following crosslinking
of cell surface CD3 molecules .
Molecular Analysis.
￿
PBMC were stimulated for 6 hand total cytoplasmic RNA was iso-
lated following NP-40 lysis. RNA was fractionated on 1% agarose-formaldehyde gels before
transfer to nylon membranes (Genescreen Plus, New England Nuclear, Boston, MA) . Filters
were hybridized overnight with "P-labeled probes and washed at high stringency (0.2 x SSC,
1% SDS at 65'C) . Full-length cDNA probes included human IL-2 (10), human cytotoxic
serine protease B (11), human IFN-y (12), human granulocyte/macrophageCSF(GM-CSF)
(13), human IL-2 receptor (14), and -y-actin (15) . Southern blot analysis was performed on
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high
molecular weight DNA isolated from an EBVtransformed B-lymphoblastoid cell line
derived
from the patient's B cells
.
Hybridization conditions were as for Northern blots
.
Case
Report
The
patient was the 8-lb male product of a full-term normal pregnancy
.
At 2 wk of age,
the
child developed eczema
.
At 2 mo of age, the child was hospitalized with bilateral otitis
media
and oral thrush
.
The patient responded to antibiotics, and was maintained on topical
mycostatin.
At 3
.5
mo the child developed a cough with persistent mucocutaneous candidi-
asis.
Chestx-ray revealed bronchiolitis
.
The patient responded to Bactrim therapy
.
Labora-
tory
evaluation at this time revealed a lymphocytosis (WBC, 22
.1
with 69% lymphocytes)
and
marked hypogammaglobulinemia (IgG 85 mg/dl
;
IgA <10 mg/dl
;
IgM 10 mg/dl)
.
Aden-
osine
deaminase and purine nucleoside phosphorylase levels were normal
.
Family history
was
notable for an older female sibling with recurrent bacterial and yeast infections, who
died
at 22 mo with autopsy-proven pneumocystis pneumonia
.
Parents and patient were HIV
antibody
negative
.
On initial evaluation, the patient was in the 10-25th percentile for weight,
length,
and head circumference
.
His exam was normal except for cutaneous candidiasis and
eczema.
Results
Our
initial evaluation of this patient's PBMC revealed an absolute lymphocyte
count
of 14,400 cells/jA1(normal range
:
2,400-10,200 cells/pl) having normal percen-
tages
of CD3+ T cells (78%) and CD20+ B cells (20%)
.
Both CD4 (helper-inducer,
62%)
and CD8 (cytotoxic-suppressor, 24%) T cell subpopulations were present
(CD4/CD8
ratio of 2
.6).
The CD4 subset contained a predominance of CD45R+
cells
(78%), as is normally seen early in life (16)
.
The T cells expressed normal levels
of
CD2, CD3, and CD7
.
Cells bearing the CD25 (IL-2 receptor) and CD71 (trans-
ferrin
receptor) antigens were absent (<1%)
.
Small but detectable numbers (1-2%)
of
cellsbearing the NK-associated markers CD16 (FcRII) and CD56 (NKH-1) were
present,
and the patient exhibited reduced but detectable lysis of the NK-sensitive
K562
target cell line (16
.6%
specific lysis at 100
:1
E/T ratio)
.
Thus, in contrast to
most
patients with SCID, this patient presented with T and B lymphocytes of in-
creased
number, but normal distribution and phenotype
.
Assays
of immune function with the patient's PBMC, however, revealed absent
or
severely impaired responses to mitogens, common antigens, and a reduced re-
sponse
in MLC compared with normal controls (Table I)
.
The combination of
ionomycin
and PMA could also induce weak proliferation
.
Addition ofpatient's PBMC
to
control MLCs failed to demonstrate any suppressor cell activity
.
Strikingly,
the addition of exogenous IL-2 to these in vitro assays completely re-
stored
the proliferative responses in a dose-dependent fashion (Table I)
.
In addition,
the
patient's PBMC proliferated and could be propagated in vitro using immobi-
lized
mAb OKT3 and exogenously supplied IL-2
.
This effect could not be sub-
stituted
by otherlymphokines including IL-1(3, IL-3, IL-4, IL-6, or GM-CSR When
PBMC
were cultured for 4 d in the presence of 100 U/ml IL-2, the number of
CD3-CD56+
NK cells increased to 9%, and the K562-specific lysis increased from
7.3
to 36
.3%
(E/T ratio of 25
:1).
Together, these data suggested that the patient's
T
cellsand NK cells could respond to, but could not produce, functional IL-2 mole-
cules.
Bioassays confirmed that IL-2 was not produced following stimulation ofPBMC
with
PHA or mAb OKT3
.
Additional
analyses ofthe T cell activation pathway were performed
.
The patient's
cells
were cultured with PHA with or without exogenous IL-2 for 3 d and the induc-Neg
C045
CD25
CD71
TABLE I
Proliferative Responses of Patient and Control PBMC
PBMC were cultured in 96-well, flat-bottomed microtiter plates at 105 cells/well
for 72 h and pulsed for the last 24 h with 1 ttCi/well of [3H]thymidine. Mito-
gens were used at : PHA, 5 tug/ml; PWM, 1/100 dilution; PMA, 5 ng/ml; iono-
mycin, 0.3 tuM. Results are the mean of three determinations with SD < 10%
of the means. One of three experiments.
tion of cell surface receptors necessary for T cell proliferation, such as the CD25
and CD71 antigens, was assessed (Fig. 1). In the absence of exogenous IL-2, pa-
tient's cells expressed the CD25 and CD71 antigens, although they were slightly di-
minished in comparison to control cells (data not shown). When exogenous IL-2
Control
￿
Patient
48
142
128
85
Log Fluorescence Intensity
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FIGURE 1.
￿
Expression of cell
surface antigens following stim-
ulation ofPBMC with 5 Rg/ml
PHA and 25 U/ml IL-2 for 3 d.
Cells were incubated with sat-
urating amounts of negative
control, CD45 (HLE), CD25
(IL2-receptor), or CD71 (OKT9)
fluoresceinated mAbs and ana-
lyzed by flow cytometry. The
scale of fluorescence intensity
ranged from 0 to 255 over three
decades of log fluorescence (85
per decade) as indicated by the
three tick marks. Upper right
hand corner for each histogram
indicates the mean fluorescence
intensity ofthe gated population
(lymphocytes).
Patient Control
Media 358 cpm 533
PHA 2,222 78,505
PWM 1,671 14,213
Iono/PMA 23,429 70,910
Media + IL-2 (U/ml) 1,329 5,521
PHA + IL-2 75,100 75,350
Iono/PMA + IL-2 75,872 88,156
Candida albicans 235 >4,000
Escherichia coli 250 >2,500
Staphylococcal aureus 215 >2,500
MLC 3,600 >5,0001700
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was added to PHA-stimulated cultures, normal amounts of the CD25 and CD71
antigens (Fig . 1), as well asMHC class II molecules (data not shown), were expressed .
The normal expression of the CD25 antigen implies that protein kinase C (PKC)
activation is not defective, as these events are linked (17) . In addition, the patient's
PBMC demonstrated a comparable rise in intracellular calcium levels after cross-
linking of surface-bound OKT3 as that seen with controlPBMC (data not shown) .
To determine the nature ofthe IL-2 production deficiency, Northern blot analysis
was performed (Fig . 2) . After cellular activation, control PBMC demonstrated a
large increase in RNAs for IL-2, IL-2 receptor, cytotoxic serine protease-B, IFN-'1',
andGM-CSR The patient's cells produced no IL-2 transcripts under any circum-
stances, although both IL-2 receptor and cytotoxic serine protease B transcripts were
readily induced . Induction ofIFN-y and GM-CSF transcripts was diminished in
patient's cells compared with normal controls, although a weak signal was detect-
able . Other lymphokine transcripts including IL-3, IL-4, and IL-6 were also present
(data not shown) . In vitro expanded patient's lymphocytesderived from short-term
(10-d) cultures using immobilized OKT3 and exogenous IL-2 were also analyzed .
As with freshly isolated PBMC, in vitro expanded patient's cells produced no IL-2
transcripts after stimulation . However, as shown in Fig . 3, IFN-yandGM-CSF tran-
scriptswere now readily detectable, indicating that transcription from these loci was
FIGURE 2 .
￿
Northern blot analysis offreshly isolatedPBMC fol-
lowing activation for6 h with (1) no stimulus, (2) 5ng/mlPMA
and 5 lug/ml PHA, or (3) 5 ng/ml PMA and 0.3 pM ionomycin .
10 Wg of total RNA was used for each filter. cDNA probes were
labeled using a-[32PJdCTP Autoradiography was for 72 h at
-70°C for all probes except actinwhichwas for 24 h at -70°C .DISANTO ET AL .
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FIGURE 3 .
￿
Northern blot analysis of 10-d in vitro expanded
PBMC following activation for 6 h with (1) no stimulus,
(2) 5 ng/ml PMA and 5pg/ml PHA, or (3) 5 ng/mlPMA
and 0.3pM ionomycin . Cells were expanded using immo-
bilizedOKT3 and25 U/ml IL-2 . Autoradiography was for
24 h at -70°C .
augmented in the presence of IL-2 . Southern blot analysis usinga full-length IL-2
cDNA probe revealed no differences in restriction patterns between patient'sDNA
and placentalDNA using avariety of enzymes (Bam HI, Bgl II, Eco RI, Hind III,
Pvu II, or Xba I ; data not shown). Allhybridizingfragmentswere as predicted from
the known organization of the human IL-2 gene locus (18) .
Discussion
Although avariety of additional growth factors existthat augmentTcell prolifer-
ation, thedominant mechanism forT cell growth is via the interaction of IL-2 with
the IL-2 receptor. This autocrine pathway is critical for the generation and main-
tenance of functional immune responses . This patient suffers from acongenital im-
munodeficiency which appears to be the consequenceof an inability ofhiscirculating
T cells to produce IL-2 . Interestingly, of the various functional assays, the MLC
response was relatively spared . This may be explained by back-production of IL-2
by the irradiated stimulator cells in response to the patient's cells, allowing the pa-
tient's cells to proliferate . The partial response to PMA and ionomycin may be due
to production ofotherlymphokines such as IL-3, IL-4, IL-6, orGM-CSF with sub-
sequent proliferationof responsive T and/ornon-T cell populations . However, long-
term in vitro growth ofT cells in response to OKT3 could only be stimulated by
exogenous IL-2, suggesting that the proliferative response toPMAand ionomycin
might involve predominantly nonT cells .
The defect appears selective to IL-2, in that cell surface receptors and other lym-
phokines canbe detected, although at diminished levels compared with control cells.
This may be in part a consequence of absent IL-2 production, as levels increase1702
￿
SCID T CELL DEVELOPMENT IN THE ABSENCE OF IL-2
with the addition of exogenous IL-2 . It is well established that the IL-2 receptor
and IFN--y expression are augmented by IL-2 (19), and it appears that GM-CSF
transcription may also be upregulated by IL-2. Although it remains possible that
deficiencies in transmembrane signaling may be involved in the IL-2 deficiency, this
seems unlikely as the patient's PBMC can mobilize intracellular calcium, and can
apparently activate PKC, as evidenced by the expression of the CD25 antigen.
Moreover, stimuli that bypass the cell surface (PMA and ionomycin) fail to induce
IL-2 transcription.
The absence of IL-2 production may involve alterations in the IL-2 gene or in
the mechanisms regulating its transcription. We found no gross structural altera-
tions in the IL-2 gene locus, although we cannot rule out a point mutation or small
deletion. Alternatively, the defect in IL-2 production may relate to an abnormality
of one of the nuclear trans-acting proteins that bind to target sequences upstream
of the IL-2 gene and regulate IL-2 transcription (20). The only T cell-specific DNA
binding protein implicated in regulating IL-2 production is NFAT1 (21). It is tempting
to speculate that the patient's defect may reside in NFAT1 or another yet unidentified
transcriptional activator. Lack of such a factor might also contribute to the diminu-
tion of the other T cell-produced lymphokines (IFN-'Y and GM-CSF).
This child's genetic disorder provides important insights into T cell development
which require further analysis. Specifically, this child developed and maintained a
normal circulating T cell pool in the absence of detectable peripheral IL-2 produc-
tion. Although IL-2 has been implicated in intrathymic T cell development (2, 3),
this child's immunodeficiency disorder suggests that prethymic and intrathymic T
cell development may occur in the setting ofan IL-2 production defect, and recipro-
cally, that IL-2 deficiencydoes not in and ofitself result in T lymphopenia. Alterna-
tively, it may suggest that intrathymic IL-2 production may be regulated by distinct
mechanisms from those that regulate IL-2 production in peripheral T cells. This
child has provided important in vivo information as to the morphologic and func-
tional consequences of peripheral IL-2 deficiency. His illness confirms the central
role of IL-2 in the immune response, but suggests that data implicating IL-2 in in-
trathymic development must either be reconsidered, or that alternative pathways
of T cell development may also exist.
Summary
We have characterized a child with a severe combined immunodeficiency disease
syndrome with increased numbers, but a normal distribution, of CD3 + T cells. This
patient's immunological defect appears to be attributable to a selective deficiency
in T cell production of IL-2, which may reflect a subtle abnormality in the IL-2
gene locus or a defect in a regulatory factor necessary for IL-2 transcription. The
increased numbers of phenotypically normal T cells in this patient suggest that al-
ternative pathways ofT cell development exist in man or that IL-2 production intra-
and extrathymically is controlled via distinct regulatory mechanisms.
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